Lee et al. [125] showed that the absence of ctDNA at baseline, or its tenfold decrease during treatment, was associated with better response and survival in metastatic melanoma patients receiving anti-PD-1 therapy. This evidence concerns the gene PDCD1 and metastatic melanoma.